Xinhua Pharma Secures Registration Certificate for Respiratory Oral Solution in China

MT Newswires Live
05/11

Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained a drug registration certificate for its Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution from China's National Medical Products Administration.

The drug is used for the treatment of acute and chronic respiratory diseases caused by cough, viscous sputum, difficult sputum excretion, and wheezing, among other things, according to a Monday Hong Kong bourse filing.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10